873
Participants
Start Date
April 20, 2022
Primary Completion Date
April 25, 2027
Study Completion Date
April 25, 2032
Radiotherapy (SBRT) and/or surgery (metastasectomy)
Metastasis-directed therapay (surgery and/or radiotherapy) as treatment for oligorecurrent lesions
Androgen deprivation therapy
Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im
Androgen receptor targeted therapy
Enzalutamide
RECRUITING
University Hospitals Leuven, Leuven
Universitaire Ziekenhuizen KU Leuven
OTHER